Molecular Pharmacology (USA) Ltd
Molecular Pharmacology (USA), Ltd., a development stage company, develops and commercializes pain and inflammation management products primarily in Australia and the United States. The company, through its subsidiary, Molecular Pharmacology Pty. Ltd., develops analgesic and anti-inflammatory molecule, known as Tripeptofen for the treatment of common every-day pain. Its products are available in v… Read more
Molecular Pharmacology (USA) Ltd (MLPH) - Total Liabilities
Latest total liabilities as of September 2014: $2.11 Million USD
Based on the latest financial reports, Molecular Pharmacology (USA) Ltd (MLPH) has total liabilities worth $2.11 Million USD as of September 2014.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Molecular Pharmacology (USA) Ltd - Total Liabilities Trend (2004–2014)
This chart illustrates how Molecular Pharmacology (USA) Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Molecular Pharmacology (USA) Ltd Competitors by Total Liabilities
The table below lists competitors of Molecular Pharmacology (USA) Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hutn Inc
PINK:HUTN
|
USA | $21.00 Million |
|
Puissant Industries Inc
PINK:PSSS
|
USA | $127.14K |
|
Hop-On Inc
PINK:HPNN
|
USA | $11.53 Million |
|
Itonis Inc
PINK:ITNS
|
USA | $1.27 Million |
Liability Composition Analysis (2004–2014)
This chart breaks down Molecular Pharmacology (USA) Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.00 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.00 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 238.32 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Molecular Pharmacology (USA) Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Molecular Pharmacology (USA) Ltd (2004–2014)
The table below shows the annual total liabilities of Molecular Pharmacology (USA) Ltd from 2004 to 2014.
| Year | Total Liabilities | Change |
|---|---|---|
| 2014-06-30 | $2.24 Million | +8.50% |
| 2013-06-30 | $2.07 Million | -1.08% |
| 2012-06-30 | $2.09 Million | +5.30% |
| 2011-06-30 | $1.98 Million | +32.37% |
| 2010-06-30 | $1.50 Million | +14.87% |
| 2009-06-30 | $1.30 Million | -4.02% |
| 2007-06-30 | $1.36 Million | +337.60% |
| 2006-06-30 | $310.58K | +12597.51% |
| 2004-06-30 | $2.45K | -- |